TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NeurAxis, Inc. ( (NRXS) ) has provided an announcement.
On July 1, 2025, NeurAxis, Inc. terminated its License and Collaboration Agreement with Masimo Corporation, which had been in place since April 9, 2020, for the NSS-2 Bridge device. As part of the termination, NeurAxis agreed to pay Masimo $200,000, resulting in the cessation of licensing payments and revenue from the device. Additionally, NeurAxis adopted a new Employee Stock Purchase Plan on the same date, allowing employees to purchase company stock at a discount, with stockholder approval required within 12 months.
The most recent analyst rating on (NRXS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.
Spark’s Take on NRXS Stock
According to Spark, TipRanks’ AI Analyst, NRXS is a Neutral.
The overall stock score is primarily impacted by significant financial risks, including negative equity and cash flow challenges. While technical analysis shows a neutral trend, and valuation metrics are weak, the earnings call provided optimistic guidance with potential for revenue growth and strategic advancements.
To see Spark’s full report on NRXS stock, click here.
More about NeurAxis, Inc.
NeurAxis, Inc. operates in the medical device industry, focusing on products that address opioid withdrawal symptoms. Its primary product, the NSS-2 Bridge, is a percutaneous nerve field stimulator used to alleviate opioid withdrawal symptoms.
Average Trading Volume: 1,660,738
Technical Sentiment Signal: Sell
See more insights into NRXS stock on TipRanks’ Stock Analysis page.